Shoemaker A R, Luongo C, Moser A R, Marton L J, Dove W F
McArdle Laboratory for Cancer Research, University of Wisconsin Medical School, Madison 53706, USA.
Cancer Res. 1997 May 15;57(10):1999-2006.
We have demonstrated previously that intestinal tumor formation in B6 Min/+ mice is always accompanied by loss of the wild-type adenomatous polyoposis coli (Apc) allele and that intestinal tumor multiplicity in B6 Min/+ mice can be significantly increased by treatment with a single dose of N-ethyl-N-nitrosourea (ENU). Here, we show that some tumors from ENU-treated Min/+ mice can form without complete elimination of Apc+. At least 25% of these tumors acquired somatic Apc truncation mutations. Interestingly, some ENU-induced tumors demonstrated loss of the Apc+ allelic marker examined by the quantitative PCR assay used here. Using two methods of mutation detection, we identified no Apc mutations in at least 12% of the tumors from ENU-treated B6 Min/+ mice. Finally, no H- or K-ras-activating mutations were detected in intestinal tumors from either untreated or ENU-treated Min/+ mice. The majority of somatic human APC mutations in intestinal tumors lead to APC truncation. Our results demonstrate that somatic Apc truncation mutations also frequently occur in ENU-induced intestinal tumors in Min mice.
我们之前已经证明,B6 Min/+小鼠的肠道肿瘤形成总是伴随着野生型腺瘤性息肉病基因(Apc)等位基因的缺失,并且用单剂量的N-乙基-N-亚硝基脲(ENU)处理可显著增加B6 Min/+小鼠的肠道肿瘤数量。在此,我们表明,ENU处理的Min/+小鼠的一些肿瘤在未完全消除Apc+的情况下即可形成。这些肿瘤中至少25%获得了体细胞Apc截短突变。有趣的是,一些ENU诱导的肿瘤显示出通过本文所用的定量PCR分析检测到的Apc+等位基因标记的缺失。使用两种突变检测方法,我们在ENU处理的B6 Min/+小鼠的至少12%的肿瘤中未发现Apc突变。最后,在未处理或ENU处理的Min/+小鼠的肠道肿瘤中均未检测到H-或K-ras激活突变。肠道肿瘤中大多数体细胞人APC突变会导致APC截短。我们的结果表明,体细胞Apc截短突变在ENU诱导的Min小鼠肠道肿瘤中也经常发生。